Jpmorgan Chase & CO Nuvation Bio Inc. Transaction History

Jpmorgan Chase & CO

  • $1.27 Trillion
  • Q1 2025

A detailed history of Jpmorgan Chase & CO transactions in Nuvation Bio Inc. stock. As of the latest transaction made, Jpmorgan Chase & CO holds 87,114 shares of NUVB stock, worth $203,846. This represents 0.0% of its overall portfolio holdings.

Number of Shares
87,114
Previous 120,115 27.47%
Holding current value
$203,846
Previous $319,000 52.04%
% of portfolio
0.0%
Previous 0.0%

Shares

20 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q1 2025

May 12, 2025
SELL
$1.76 - $3.25 $58,081 - $107,253
-33,001 Reduced 27.47%
87,114 $153,000
Q4 2024

Feb 12, 2025
SELL
$2.01 - $3.01 $648,823 - $971,621
-322,798 Reduced 72.88%
120,115 $319,000
Q3 2024

Dec 26, 2024
BUY
$2.3 - $3.83 $842,786 - $1.4 Million
366,429 Added 479.09%
442,913 $1.02 Million
Q3 2024

Nov 08, 2024
BUY
$2.3 - $3.83 $842,786 - $1.4 Million
366,429 Added 479.09%
442,913 $1.02 Million
Q2 2024

Dec 26, 2024
SELL
$2.58 - $3.69 $945,386 - $1.35 Million
-366,429 Reduced 82.73%
76,484 $223,000
Q2 2024

Aug 12, 2024
BUY
$2.58 - $3.69 $47,250 - $67,578
18,314 Added 31.48%
76,484 $223,000
Q1 2024

Dec 26, 2024
SELL
$1.46 - $3.97 $561,724 - $1.53 Million
-384,743 Reduced 86.87%
58,170 $211,000
Q1 2024

May 10, 2024
SELL
$1.46 - $3.97 $59,414 - $161,559
-40,695 Reduced 41.16%
58,170 $211,000
Q4 2023

Dec 26, 2024
SELL
$0.96 - $1.53 $330,286 - $526,393
-344,048 Reduced 77.68%
98,865 $149,000
Q4 2023

Feb 12, 2024
SELL
$0.96 - $1.53 $612 - $976
-638 Reduced 0.64%
98,865 $149,000
Q3 2023

Nov 14, 2023
SELL
$1.26 - $2.1 $17,750 - $29,584
-14,088 Reduced 12.4%
99,503 $133,000
Q2 2023

Aug 11, 2023
BUY
$1.56 - $1.84 $36,911 - $43,536
23,661 Added 26.31%
113,591 $204,000
Q1 2023

May 18, 2023
BUY
$1.6 - $2.48 $142,665 - $221,131
89,166 Added 11670.94%
89,930 $149,000
Q1 2023

May 11, 2023
SELL
$1.6 - $2.48 $105,452 - $163,451
-65,908 Reduced 98.85%
764 $1,000
Q4 2022

Feb 13, 2023
BUY
$1.68 - $2.5 $3,012 - $4,482
1,793 Added 2.76%
66,672 $128,000
Q3 2022

Nov 14, 2022
SELL
$0.29 - $4.04 $38,227 - $532,552
-131,820 Reduced 67.02%
64,879 $145,000
Q2 2022

Aug 11, 2022
SELL
$3.24 - $5.85 $1.68 Million - $3.03 Million
-518,701 Reduced 72.51%
196,699 $638,000
Q1 2022

May 11, 2022
BUY
$4.6 - $8.83 $198,623 - $381,270
43,179 Added 6.42%
715,400 $3.76 Million
Q4 2021

Feb 10, 2022
BUY
$7.75 - $10.05 $4.81 Million - $6.23 Million
620,362 Added 1196.25%
672,221 $5.71 Million
Q3 2021

Nov 12, 2021
BUY
$7.78 - $10.0 $403,463 - $518,590
51,859 New
51,859 $516,000

Others Institutions Holding NUVB

# of Institutions
167
Shares Held
156M
Call Options Held
4.6K
Put Options Held
154K
View Full List

About Nuvation Bio Inc.

NUVB Quotes by TradingView
  • Ticker NUVB
  • Exchange NYSE
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 217,244,000
  • Market Cap $508M
  • Description
  • Nuvation Bio Inc., a clinical-stage biopharmaceutical company, focuses on the development of therapeutic candidates for oncology. The company's lead product candidate is NUV-422, a small molecule inhibitor targeting cyclin-dependent kinase (CDK)2, CDK4, and CDK6. It is also developing NUV-868, a selective oral small molecule BET inhibitor that e...
More about NUVB
Track This Portfolio

Track Jpmorgan Chase & CO Portfolio

Follow Jpmorgan Chase & CO and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Jpmorgan Chase & CO, based on Form 13F filings with the SEC.

News

Stay updated on Jpmorgan Chase & CO with notifications on news.

Choose your preferred platform and Sign Up 👇 Telegram Email